“The Applicant evaluated the safety of repotrectinib administered orally once daily in 28-day and 91-day GLP-compliant general toxicology studies using rats and cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Why that species
100% sequence homology of target binding sites with human and similar metabolism
“Rats (Sprague-Dawley) and monkeys (cynomolgus) are considered relevant toxicological species based on 100% sequence homology for the target binding sites and similar metabolism.”
“The Applicant evaluated the safety of repotrectinib administered orally once daily in 28-day and 91-day GLP-compliant general toxicology studies using rats and cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: general tox
Rat and cynomolgus monkey (28-day and 91-day oral)
“The Applicant evaluated the safety of repotrectinib administered orally once daily in 28-day and 91-day GLP-compliant general toxicology studies using rats and cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: DART
Rat (dose-range-finding EFD)
“Reproductive and developmental toxicology assessment of repotrectinib included a dose range finding embryofetal development study in female rats with orally administered repotrectinib.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: carcinogenicity
Not conducted (not warranted for the indication)
“Carcinogenicity studies have not been conducted with repotrectinib and are not warranted for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Surrogate used in
No surrogate used; repotrectinib tested directly
“The Applicant evaluated the safety of repotrectinib administered orally once daily in 28-day and 91-day GLP-compliant general toxicology studies using rats and cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗